German medtech sector sales grow 5.5% in 2010
12 Nov 2010
A survey by BVMed, the German Medical Technology Association,
has found that sales of the German medical technology sector in 2010
have grown by 5.5%.
Companies in the German medical technology sector also continue to
be strong on innovation and growth, creating new jobs.
The BVMed autumn survey included 139 member companies.
overall economic development of the industry is good. Over 80%of the
Medtech companies surveyed expect to see sales growth this year
outperform 2009. Growth in sales this year comes in at around 5.5%,
compared to the previous year 2009, a year of crisis, when it rated
3%," explained Dr Meinrad Lugan, BVMed Chairman of the Board.
However, the profit situation has been diminished due to a
substantial rise in the prices of raw materials and a higher rate of
late payments. Thus, companies are only cautiously optimistic in
their outlook for 2011: 48% expect better profit results than this
year; 17% actually expect to see a decline in profits.
survey shows the medical technology sector to be a main driver of
jobs as before. Half of the companies surveyed have created new
jobs, compared to the previous year — 96% of companies have
Dr Lugan continued: "In this way, the Medtech industry is not only
making an outstanding contribution to the health sector but is also
a source of hope for the German labour market."
comes to health-policy demands, the issue of "debureaucratization
and accelerating decision-making" takes centre-stage — 60% of
companies cite these aspects as the most important demands. This is
mainly directed at the Joint Federal Committee. Accordingly, a
quarter of the companies favour a reform of self-governing bodies —
with a greater degree of political legitimacy, more transparency and
rights of participation as well as clear time-limit provisions.
Overall, Germany is given good marks as business location by the
Medtech companies. 60% see a high level of patient care. As examples
of Germany´s great strengths are given: well-trained physicians
(57%), a high standard of clinical research (48%), well-educated
engineers (39%) and highly-qualified scientists (34%).
The majority of companies, however, see a weakness in the
reimbursement system. Only a quarter consider the general conditions
governing the reimbursement for medical products to be stable. Only
23% of the companies are satisfied with the level of reimbursement